Only 8% of Symptomatic Women Receive a Perimenopause or Menopause Diagnosis
A large-scale analysis finds that more than half of women aged 40-64 experience perimenopause or menopause symptoms, yet only 8% receive a confirmed diagnosis — exposing a systemic recognition gap in clinical care.
Read the original article at Evernorth / npj Women's HealthKairos™'s Take
Kairos™'s perspective on this story
Published in npj Women's Health in March 2025, this study examined perimenopause symptom prevalence and healthcare-seeking behavior among U.S. women. The finding that stands out: more than half of women aged 40 to 64 reported symptoms consistent with perimenopause or menopause, yet only 8% had received a confirmed diagnosis. This is not a subtle gap — it is a system-wide failure of clinical recognition. The study documents that moderate to severe vasomotor symptoms are nearly five times more prevalent in perimenopause than in premenopause, and vaginal dryness occurs 2.5 times more often. Psychological symptoms — anxiety, depression, irritability — often appear before the physical symptoms, peaking among women aged 41 to 45.
The diagnostic challenge is real. No single biomarker reliably confirms perimenopause onset. FSH, the most commonly ordered test, fluctuates widely during the transition — a normal result one month can be elevated the next. Women with regular cycles and non-specific symptoms often cannot connect their experience to perimenopause, and clinicians frequently lack adequate training in perimenopause care. Overlapping conditions like thyroid dysfunction, PCOS, and mood disorders further complicate the picture. The result is a population of women who are symptomatic, confused about the cause, and under-treated — not because effective treatments do not exist, but because the diagnostic conversation never happens.
Why This Matters
An 8% diagnosis rate against a prevalence of over 50% is not a knowledge problem — it is an infrastructure problem. The clinical system does not systematically ask, track, or flag the patterns that would make perimenopause recognizable. This is precisely the gap that longitudinal health monitoring can fill. When a woman tracks her cycle lengths, vasomotor episodes, sleep quality, mood patterns, and cognitive symptoms over months, the data itself becomes diagnostic. A pattern of increasing cycle variability with concurrent vasomotor and mood symptoms, captured in a structured timeline, tells a story that a single office visit cannot. It does not replace clinical judgment — it gives clinical judgment something to work with.
Ready to start tracking?
Kairos™ tracks, scores, and interprets the symptoms of midlife hormonal change — for both women and men.
Get StartedMore from the newsroom
England Adds Menopause to Routine NHS Health Checks for Nearly 5 Million Women
The UK government announced that menopause will be integrated into routine NHS health checks for women aged 40 to 74 — the first time the national health system has systematically screened for menopause symptoms.
Sleep Disruption in Menopause: No Approved Therapy Exists for the Most Common Complaint
A review in Menopause reveals that despite affecting 40-56% of peri- and postmenopausal women, sleep disturbance associated with menopause has no specifically approved pharmacological treatment.
The WHI at 30: How One Trial Reshaped Hormone Therapy for a Generation
A comprehensive JAMA review revisits the Women's Health Initiative 30 years after launch, clarifying what the landmark trial actually found and what it means for clinical practice today.